PubMed:32031570 / 1985-2212
Annnotations
LitCovid-OGER-BB
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T8 | 42-53 | CHEBI:7798 | denotes | oseltamivir |
T9 | 42-53 | CHEBI:7798 | denotes | oseltamivir |
T10 | 110-122 | CHEBI:63611 | denotes | moxifloxacin |
T11 | 110-122 | CHEBI:63611 | denotes | moxifloxacin |
T12 | 136-147 | CHEBI:29007 | denotes | ceftriaxone |
T13 | 136-147 | CHEBI:29007 | denotes | ceftriaxone |
T14 | 161-173 | CHEBI:2955 | denotes | azithromycin |
T15 | 161-173 | CHEBI:2955 | denotes | azithromycin |
T16 | 161-173 | DG_6 | denotes | azithromycin |
T17 | 191-205 | CHEBI:24261 | denotes | glucocorticoid |
T18 | 191-205 | CHEBI:24261 | denotes | glucocorticoid |
LitCovid-PAS-Enju
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
EnjuParser_T360 | 0-4 | JJS | denotes | Most |
EnjuParser_T361 | 5-13 | NNS | denotes | patients |
EnjuParser_T362 | 14-22 | VBD | denotes | received |
EnjuParser_T363 | 23-32 | JJ | denotes | antiviral |
EnjuParser_T364 | 33-40 | NN | denotes | therapy |
EnjuParser_T365 | 41-42 | -LRB- | denotes | ( |
EnjuParser_T366 | 42-53 | NN | denotes | oseltamivir |
EnjuParser_T367 | 53-54 | -COMMA- | denotes | , |
EnjuParser_T368 | 55-58 | CD | denotes | 124 |
EnjuParser_T369 | 59-60 | -LRB- | denotes | [ |
EnjuParser_T370 | 60-64 | CD | denotes | 89.9 |
EnjuParser_T371 | 64-65 | NN | denotes | % |
EnjuParser_T372 | 65-66 | -RRB- | denotes | ] |
EnjuParser_T373 | 66-67 | -RRB- | denotes | ) |
EnjuParser_T374 | 67-68 | -COMMA- | denotes | , |
EnjuParser_T375 | 69-72 | CC | denotes | and |
EnjuParser_T376 | 73-77 | JJ | denotes | many |
EnjuParser_T377 | 78-86 | VBD | denotes | received |
EnjuParser_T378 | 87-100 | JJ | denotes | antibacterial |
EnjuParser_T379 | 101-108 | NN | denotes | therapy |
EnjuParser_T380 | 109-110 | -LRB- | denotes | ( |
EnjuParser_T381 | 110-122 | NN | denotes | moxifloxacin |
EnjuParser_T382 | 122-123 | -COMMA- | denotes | , |
EnjuParser_T383 | 124-126 | CD | denotes | 89 |
EnjuParser_T384 | 127-128 | -LRB- | denotes | [ |
EnjuParser_T385 | 128-132 | CD | denotes | 64.4 |
EnjuParser_T386 | 132-133 | NN | denotes | % |
EnjuParser_T387 | 133-134 | -RRB- | denotes | ] |
EnjuParser_T388 | 134-135 | -SEMICOLON- | denotes | ; |
EnjuParser_T389 | 136-147 | NN | denotes | ceftriaxone |
EnjuParser_T390 | 147-148 | -COMMA- | denotes | , |
EnjuParser_T391 | 149-151 | CD | denotes | 34 |
EnjuParser_T392 | 152-153 | -LRB- | denotes | [ |
EnjuParser_T393 | 153-157 | CD | denotes | 24.6 |
EnjuParser_T394 | 157-158 | NN | denotes | % |
EnjuParser_T395 | 158-159 | -RRB- | denotes | ] |
EnjuParser_T396 | 159-160 | -SEMICOLON- | denotes | ; |
EnjuParser_T397 | 161-173 | NN | denotes | azithromycin |
EnjuParser_T398 | 173-174 | -COMMA- | denotes | , |
EnjuParser_T399 | 175-177 | CD | denotes | 25 |
EnjuParser_T400 | 178-179 | -LRB- | denotes | [ |
EnjuParser_T401 | 179-183 | CD | denotes | 18.1 |
EnjuParser_T402 | 183-184 | NN | denotes | % |
EnjuParser_T403 | 184-185 | -RRB- | denotes | ] |
EnjuParser_T404 | 185-186 | -RRB- | denotes | ) |
EnjuParser_T405 | 187-190 | CC | denotes | and |
EnjuParser_T406 | 191-205 | NN | denotes | glucocorticoid |
EnjuParser_T407 | 206-213 | NN | denotes | therapy |
EnjuParser_T408 | 214-215 | -LRB- | denotes | ( |
EnjuParser_T409 | 215-217 | CD | denotes | 62 |
EnjuParser_T410 | 218-219 | -LRB- | denotes | [ |
EnjuParser_T411 | 219-223 | CD | denotes | 44.9 |
EnjuParser_T412 | 223-224 | NN | denotes | % |
EnjuParser_T413 | 224-225 | -RRB- | denotes | ] |
EnjuParser_T414 | 225-226 | -RRB- | denotes | ) |
EnjuParser_R358 | EnjuParser_T361 | EnjuParser_T360 | arg1Of | patients,Most |
EnjuParser_R359 | EnjuParser_T361 | EnjuParser_T362 | arg1Of | patients,received |
EnjuParser_R360 | EnjuParser_T364 | EnjuParser_T362 | arg2Of | therapy,received |
EnjuParser_R361 | EnjuParser_T364 | EnjuParser_T363 | arg1Of | therapy,antiviral |
EnjuParser_R362 | EnjuParser_T364 | EnjuParser_T365 | arg1Of | therapy,( |
EnjuParser_R363 | EnjuParser_T366 | EnjuParser_T365 | arg2Of | oseltamivir,( |
EnjuParser_R364 | EnjuParser_T373 | EnjuParser_T365 | arg3Of | ),( |
EnjuParser_R365 | EnjuParser_T366 | EnjuParser_T367 | arg1Of | oseltamivir,"," |
EnjuParser_R366 | EnjuParser_T368 | EnjuParser_T367 | arg2Of | 124,"," |
EnjuParser_R367 | EnjuParser_T368 | EnjuParser_T369 | arg1Of | 124,[ |
EnjuParser_R368 | EnjuParser_T371 | EnjuParser_T369 | arg2Of | %,[ |
EnjuParser_R369 | EnjuParser_T372 | EnjuParser_T369 | arg3Of | ],[ |
EnjuParser_R370 | EnjuParser_T371 | EnjuParser_T370 | arg1Of | %,89.9 |
EnjuParser_R371 | EnjuParser_T375 | EnjuParser_T374 | arg1Of | and,"," |
EnjuParser_R372 | EnjuParser_T362 | EnjuParser_T375 | arg1Of | received,and |
EnjuParser_R373 | EnjuParser_T377 | EnjuParser_T375 | arg2Of | received,and |
EnjuParser_R374 | EnjuParser_T376 | EnjuParser_T377 | arg1Of | many,received |
EnjuParser_R375 | EnjuParser_T405 | EnjuParser_T377 | arg2Of | and,received |
EnjuParser_R376 | EnjuParser_T379 | EnjuParser_T378 | arg1Of | therapy,antibacterial |
EnjuParser_R377 | EnjuParser_T379 | EnjuParser_T380 | arg1Of | therapy,( |
EnjuParser_R378 | EnjuParser_T381 | EnjuParser_T380 | arg2Of | moxifloxacin,( |
EnjuParser_R379 | EnjuParser_T404 | EnjuParser_T380 | arg3Of | ),( |
EnjuParser_R380 | EnjuParser_T381 | EnjuParser_T382 | arg1Of | moxifloxacin,"," |
EnjuParser_R381 | EnjuParser_T383 | EnjuParser_T382 | arg2Of | 89,"," |
EnjuParser_R382 | EnjuParser_T383 | EnjuParser_T384 | arg1Of | 89,[ |
EnjuParser_R383 | EnjuParser_T386 | EnjuParser_T384 | arg2Of | %,[ |
EnjuParser_R384 | EnjuParser_T387 | EnjuParser_T384 | arg3Of | ],[ |
EnjuParser_R385 | EnjuParser_T386 | EnjuParser_T385 | arg1Of | %,64.4 |
EnjuParser_R386 | EnjuParser_T381 | EnjuParser_T388 | arg1Of | moxifloxacin,; |
EnjuParser_R387 | EnjuParser_T389 | EnjuParser_T388 | arg2Of | ceftriaxone,; |
EnjuParser_R388 | EnjuParser_T389 | EnjuParser_T390 | arg1Of | ceftriaxone,"," |
EnjuParser_R389 | EnjuParser_T391 | EnjuParser_T390 | arg2Of | 34,"," |
EnjuParser_R390 | EnjuParser_T391 | EnjuParser_T392 | arg1Of | 34,[ |
EnjuParser_R391 | EnjuParser_T394 | EnjuParser_T392 | arg2Of | %,[ |
EnjuParser_R392 | EnjuParser_T395 | EnjuParser_T392 | arg3Of | ],[ |
EnjuParser_R393 | EnjuParser_T394 | EnjuParser_T393 | arg1Of | %,24.6 |
EnjuParser_R394 | EnjuParser_T381 | EnjuParser_T396 | arg1Of | moxifloxacin,; |
EnjuParser_R395 | EnjuParser_T397 | EnjuParser_T396 | arg2Of | azithromycin,; |
EnjuParser_R396 | EnjuParser_T397 | EnjuParser_T398 | arg1Of | azithromycin,"," |
EnjuParser_R397 | EnjuParser_T399 | EnjuParser_T398 | arg2Of | 25,"," |
EnjuParser_R398 | EnjuParser_T399 | EnjuParser_T400 | arg1Of | 25,[ |
EnjuParser_R399 | EnjuParser_T402 | EnjuParser_T400 | arg2Of | %,[ |
EnjuParser_R400 | EnjuParser_T403 | EnjuParser_T400 | arg3Of | ],[ |
EnjuParser_R401 | EnjuParser_T402 | EnjuParser_T401 | arg1Of | %,18.1 |
EnjuParser_R402 | EnjuParser_T379 | EnjuParser_T405 | arg1Of | therapy,and |
EnjuParser_R403 | EnjuParser_T407 | EnjuParser_T405 | arg2Of | therapy,and |
EnjuParser_R404 | EnjuParser_T407 | EnjuParser_T406 | arg1Of | therapy,glucocorticoid |
EnjuParser_R405 | EnjuParser_T407 | EnjuParser_T408 | arg1Of | therapy,( |
EnjuParser_R406 | EnjuParser_T409 | EnjuParser_T408 | arg2Of | 62,( |
EnjuParser_R407 | EnjuParser_T414 | EnjuParser_T408 | arg3Of | ),( |
EnjuParser_R408 | EnjuParser_T409 | EnjuParser_T410 | arg1Of | 62,[ |
EnjuParser_R409 | EnjuParser_T412 | EnjuParser_T410 | arg2Of | %,[ |
EnjuParser_R410 | EnjuParser_T413 | EnjuParser_T410 | arg3Of | ],[ |
EnjuParser_R411 | EnjuParser_T412 | EnjuParser_T411 | arg1Of | %,44.9 |
LitCovid-ArguminSci
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T11 | 0-227 | DRI_Background | denotes | Most patients received antiviral therapy (oseltamivir, 124 [89.9%]), and many received antibacterial therapy (moxifloxacin, 89 [64.4%]; ceftriaxone, 34 [24.6%]; azithromycin, 25 [18.1%]) and glucocorticoid therapy (62 [44.9%]). |
LitCovid-OGER
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T2 | 42-53 | CHEBI:7798 | denotes | oseltamivir |
T3 | 110-122 | CHEBI:63611 | denotes | moxifloxacin |
T4 | 136-147 | CHEBI:29007 | denotes | ceftriaxone |
T5 | 161-173 | CHEBI:2955 | denotes | azithromycin |
T6 | 191-205 | CHEBI:24261 | denotes | glucocorticoid |
LitCovid-PubTatorCentral
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T26 | 5-13 | Species:9606 | denotes | patients |
T27 | 42-53 | Chemical:MESH:D053139 | denotes | oseltamivir |
T28 | 110-122 | Chemical:MESH:C104727 | denotes | moxifloxacin |
T29 | 136-147 | Chemical:MESH:D002443 | denotes | ceftriaxone |
T30 | 161-173 | Chemical:MESH:D017963 | denotes | azithromycin |
LitCovid-sentences-v1
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
TextSentencer_T21 | 0-227 | Sentence | denotes | Most patients received antiviral therapy (oseltamivir, 124 [89.9%]), and many received antibacterial therapy (moxifloxacin, 89 [64.4%]; ceftriaxone, 34 [24.6%]; azithromycin, 25 [18.1%]) and glucocorticoid therapy (62 [44.9%]). |
LitCovid-TimeML
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
tok421 | 0-4 | JJS | denotes | Most |
tok422 | 5-13 | NNS | denotes | patients |
tok423 | 14-22 | VBD | denotes | received |
tok424 | 23-32 | JJ | denotes | antiviral |
tok425 | 33-40 | NN | denotes | therapy |
tok426 | 41-42 | ( | denotes | ( |
tok427 | 42-53 | NN | denotes | oseltamivir |
tok428 | 53-54 | , | denotes | , |
tok429 | 55-58 | CD | denotes | 124 |
tok430 | 59-60 | NN | denotes | [ |
tok431 | 60-62 | CD | denotes | 89 |
tok432 | 62-63 | . | denotes | . |
tok433 | 63-64 | CD | denotes | 9 |
tok434 | 64-65 | NN | denotes | % |
tok435 | 65-66 | NN | denotes | ] |
tok436 | 66-67 | ) | denotes | ) |
tok437 | 67-68 | , | denotes | , |
tok438 | 69-72 | CC | denotes | and |
tok439 | 73-77 | JJ | denotes | many |
tok440 | 78-86 | JJ | denotes | received |
tok441 | 87-100 | NN | denotes | antibacterial |
tok442 | 101-108 | NN | denotes | therapy |
tok443 | 109-110 | ( | denotes | ( |
tok444 | 110-122 | NN | denotes | moxifloxacin |
tok445 | 122-123 | , | denotes | , |
tok446 | 124-126 | CD | denotes | 89 |
tok447 | 127-128 | NN | denotes | [ |
tok448 | 128-130 | CD | denotes | 64 |
tok449 | 130-131 | . | denotes | . |
tok450 | 131-132 | CD | denotes | 4 |
tok451 | 132-133 | NN | denotes | % |
tok452 | 133-134 | NN | denotes | ] |
tok453 | 134-135 | : | denotes | ; |
tok454 | 136-147 | NN | denotes | ceftriaxone |
tok455 | 147-148 | , | denotes | , |
tok456 | 149-151 | CD | denotes | 34 |
tok457 | 152-153 | NN | denotes | [ |
tok458 | 153-155 | CD | denotes | 24 |
tok459 | 155-156 | . | denotes | . |
tok460 | 156-157 | CD | denotes | 6 |
tok461 | 157-158 | NN | denotes | % |
tok462 | 158-159 | NN | denotes | ] |
tok463 | 159-160 | : | denotes | ; |
tok464 | 161-173 | NN | denotes | azithromycin |
tok465 | 173-174 | , | denotes | , |
tok466 | 175-177 | CD | denotes | 25 |
tok467 | 178-179 | NN | denotes | [ |
tok468 | 179-181 | CD | denotes | 18 |
tok469 | 181-182 | . | denotes | . |
tok470 | 182-183 | CD | denotes | 1 |
tok471 | 183-184 | NN | denotes | % |
tok472 | 184-185 | NN | denotes | ] |
tok473 | 185-186 | ) | denotes | ) |
tok474 | 187-190 | CC | denotes | and |
tok475 | 191-205 | NN | denotes | glucocorticoid |
tok476 | 206-213 | NN | denotes | therapy |
tok477 | 214-215 | ( | denotes | ( |
tok478 | 215-217 | CD | denotes | 62 |
tok479 | 218-219 | NN | denotes | [ |
tok480 | 219-221 | CD | denotes | 44 |
tok481 | 221-222 | . | denotes | . |
tok482 | 222-223 | CD | denotes | 9 |
tok483 | 223-224 | NN | denotes | % |
tok484 | 224-225 | NN | denotes | ] |
tok485 | 225-226 | ) | denotes | ) |
tok486 | 226-227 | . | denotes | . |
lookup49 | 64-65 | percent | denotes | % |
lookup50 | 132-133 | percent | denotes | % |
lookup51 | 157-158 | percent | denotes | % |
lookup52 | 183-184 | percent | denotes | % |
lookup53 | 223-224 | percent | denotes | % |
event14 | 14-22 | OCCURRENCE | denotes | received |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T9 | 149-151 | http://purl.obolibrary.org/obo/CLO_0001302 | denotes | 34 |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T2 | 23-32 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
T3 | 42-53 | Chemical | denotes | oseltamivir | http://purl.obolibrary.org/obo/CHEBI_7798 |
T4 | 110-122 | Chemical | denotes | moxifloxacin | http://purl.obolibrary.org/obo/CHEBI_63611 |
T5 | 136-147 | Chemical | denotes | ceftriaxone | http://purl.obolibrary.org/obo/CHEBI_29007 |
T6 | 161-173 | Chemical | denotes | azithromycin | http://purl.obolibrary.org/obo/CHEBI_2955 |
T7 | 191-205 | Chemical | denotes | glucocorticoid | http://purl.obolibrary.org/obo/CHEBI_24261 |
MeasurableQuantitativeAnnotation
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
E1 | 23-40 | entity | denotes | antiviral therapy |
E2 | 42-53 | entity | denotes | oseltamivir |
E3 | 87-108 | entity | denotes | antibacterial therapy |
E4 | 110-122 | entity | denotes | moxifloxacin |
N1 | 55-58 | num | denotes | 124 |
N2 | 60-64 | num | denotes | 89.9 |
N3 | 124-126 | num | denotes | 89 |
N4 | 128-132 | num | denotes | 64.4 |
U1 | 64-65 | unit | denotes | % |
U2 | 132-133 | unit | denotes | % |
E1 | 136-147 | entity | denotes | ceftriaxone |
N1 | 149-151 | num | denotes | 34 |
N2 | 153-157 | num | denotes | 24.6 |
U1 | 157-158 | unit | denotes | % |
E1 | 161-173 | entity | denotes | azithromycin |
E2 | 191-213 | entity | denotes | glucocorticoid therapy |
N1 | 175-177 | num | denotes | 25 |
N2 | 179-183 | num | denotes | 18.1 |
N3 | 215-217 | num | denotes | 62 |
N4 | 219-223 | num | denotes | 44.9 |
U1 | 183-184 | unit | denotes | % |
U2 | 223-224 | unit | denotes | % |
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
73 | 5-13 | Species | denotes | patients | Tax:9606 |
74 | 42-53 | Chemical | denotes | oseltamivir | MESH:D053139 |
75 | 110-122 | Chemical | denotes | moxifloxacin | MESH:D000077266 |
76 | 136-147 | Chemical | denotes | ceftriaxone | MESH:D002443 |
77 | 161-173 | Chemical | denotes | azithromycin | MESH:D017963 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T21 | 0-227 | Sentence | denotes | Most patients received antiviral therapy (oseltamivir, 124 [89.9%]), and many received antibacterial therapy (moxifloxacin, 89 [64.4%]; ceftriaxone, 34 [24.6%]; azithromycin, 25 [18.1%]) and glucocorticoid therapy (62 [44.9%]). |